Ayen News

Category: Health & Science

  • Novel Review: No. 1, Akashganga Lane Highlights Kolkata’s Gig Economy

    NEW DELHI (Saturday, April 4, 2026) — A new novel titled No. 1, Akashganga Lane: The First Novel about the Gig Workers of Kolkata has been released, offering a raw, fictionalized look into the lives of India’s rapidly growing “invisible” workforce. Written by acclaimed author Ashoke Mukhopadhay and translated from Bengali by Zenith Roy, the book explores the precarious existence of app-based delivery partners and bike-taxi riders in a post-pandemic urban landscape.

    The Narrative: Life on “Borrowed Time”

    The story centers on Sriman Kundu, a delivery rider whose life is a constant gamble against exhaustion, traffic, and digital algorithms. The novel depicts a world of deep “disconnection”—where riders ferry meals they cannot afford to people they will never know.

    • Dual Perspectives: The book also features Mrittika Sen, a female bike-taxi driver who navigates the additional layers of danger and harassment faced by women in the gig economy.
    • The Setting: Much of the solace found by these workers occurs at a century-old house on Akashganga Lane, home to Bishan Basu, an elderly man who bridges the gap between the riders’ harsh reality and his own celestial observations through a telescope.
    • Themes of Resistance: As the plot unfolds, the characters begin to dream of solidarity and fair wages, questioning if they can afford the luxury of a strike when their survival depends on every single kilometer.

    [Image: Artistic representation of a gig worker in the crowded streets of Kolkata]

    Context: India’s Booming (and Vulnerable) Gig Economy

    The novel’s release coincides with a massive shift in India’s labour market, as highlighted by recent economic data and government projections.

    MetricProjection / Status (2026)
    Global RankIndia currently ranks 5th globally in total gig workers.
    Growth ForecastPredicted to reach 23.5 million workers by 2029-30 (NITI Aayog).
    Economic ValueValued at approximately USD 20 Billion with 17% annual growth.
    Avg. EarningsRoughly ₹15,000 per month for full-time platform work.

    The “Informal” Trap

    Experts note that while the gig economy offers flexible “gigs,” it often lacks the safety nets of traditional employment.

    1. Status: Workers are classified as “independent contractors,” which exempts platforms from providing provident funds, pensions, or paid leave.
    2. Health Risks: Long hours lead to chronic spinal problems, lung damage from pollution, and stomach ailments.
    3. Digital Erasure: A single low rating or an algorithmic change can “erase” a worker’s livelihood overnight without recourse.

    Sources

    • Ashoke Mukhopadhay: No. 1, Akashganga Lane (Niyogi Books, 2026).
    • NITI Aayog: “India’s Booming Gig and Platform Economy” (Report, 2022/2026 Updates).
    • Hindustan Times: “New book explores lives of Kolkata’s gig workers” (April 4, 2026).
    • United News of India (UNI): “Book on ordeal of gig workers released in Kolkata” (February 27, 2026).

  • Union Ayush Ministry Launches National Yoga Protocol to Combat Lifestyle Diseases

    NEW DELHI (Sunday, March 29, 2026) — In a major strategic shift toward preventive healthcare, the Union Ministry of Ayush has officially launched the “Yoga Protocol for Non-Communicable Diseases (NCDs) and Target Groups.” Introduced by Union Ayush Minister Prataprao Jadhav during the Yoga Mahotsav 2026, the initiative aims to integrate standardized Yogic practices into the national primary healthcare framework to tackle the rising burden of lifestyle-related ailments.

    The Vision: From Treatment to Prevention

    The protocol is designed to address the “silent epidemic” of NCDs, which currently account for over 60% of all deaths in India. By standardizing Yoga asanas and pranayama for specific health conditions, the Ministry seeks to provide a scientifically validated alternative for disease management.

    • Target Conditions: Diabetes, Hypertension, Cardiovascular diseases, Chronic Respiratory disorders, and Obesity.
    • Special Target Groups: Protocols have also been customized for specific demographics, including Pregnant Women, Senior Citizens, and Adolescents dealing with stress.
    • Global Standards: The initiative was developed by the WHO Collaborating Centre for Traditional Medicine (Yoga) at the Morarji Desai National Institute of Yoga (MDNIY), ensuring the practices align with international health benchmarks.

    Key Features of the Yoga Protocol

    The protocol is not a “one size fits all” routine but a modular system that can be adapted based on a patient’s clinical profile.

    ComponentFocus AreaIntended Benefit
    Suksma VyayamaJoint loosening & Warm-upsImproving flexibility and circulation in sedentary patients.
    Specific AsanasCondition-based posturesManaging glycemic index and blood pressure levels.
    PranayamaBreath regulationReducing sympathetic nervous system activity (stress reduction).
    Dhyana (Meditation)Mental well-beingEnhancing cognitive resilience and emotional balance.

    Institutional Rollout

    The Ayush Ministry plans to implement these protocols through the existing network of Ayushman Bharat Health and Wellness Centres (AB-HWCs) across the country.

    1. Training: Specialized training programs for Yoga instructors and healthcare workers to ensure correct posture and safety.
    2. Digital Integration: The protocol will be available via the “mYoga” app (developed with WHO) to allow citizens to practice at home with guided instructions.
    3. Research & Monitoring: MDNIY will lead a longitudinal study to track the impact of these protocols on the medication dependency of NCD patients.

    Sources

    • Ministry of Ayush: Official Press Release, “Launch of Yoga Protocol for NCDs” (March 2026).
    • Press Trust of India (PTI): “Ayush Ministry pushes for Yoga in NCD management; launches new protocol” (March 29, 2026).
    • World Health Organisation (WHO): Regional Briefing on Traditional Medicine Integration (March 2026).
    • The Economic Times: “India targets lifestyle diseases with new WHO-backed Yoga protocol” (March 29, 2026).

  • Global Analysis: India Achieves 80% Reduction in Maternal Mortality (1990–2023)

    NEW DELHI (Saturday, March 28, 2026) — A comprehensive global study published in The Lancet Obstetrics, Gynaecology, and Women’s Health has revealed that India’s Maternal Mortality Ratio (MMR) plummeted by nearly 80% over the last three decades. The analysis, conducted by the Institute for Health Metrics and Evaluation (IHME), highlights a significant shift in maternal health outcomes despite a recent global slowdown in progress.

    Key Findings: The Shift from 1990 to 2023

    The study tracks the transition of India from a high-burden nation to one making rapid strides toward international safety benchmarks.

    • MMR Decline: India’s ratio dropped from 508 per lakh live births in 1990 to 116 per lakh live births in 2023.
    • Total Deaths: In 2023, India recorded 24,700 maternal deaths. While this absolute number remains high due to India’s large population, the rate of survival has improved dramatically.
    • Leading Causes: Globally, and within South Asia, maternal hemorrhage (excessive bleeding) and hypertensive disorders (like pre-eclampsia) remain the primary drivers of mortality, accounting for over 40% of cases.

    Global and Regional Comparison (2023)

    The analysis places India’s progress in context with other high-population nations in South Asia and Sub-Saharan Africa.

    CountryTotal Maternal Deaths (2023)MMR (per 1 lakh live births)
    Nigeria32,900Highest global burden
    India24,700116
    Ethiopia11,900High Sub-Saharan burden
    Pakistan10,300Notable South Asian burden

    Stagnation and Future Challenges

    The researchers noted that while the 30-year trend is positive, global progress has “stagnated” since 2015.

    • The 2030 Goal: 104 out of 204 countries studied are currently off-track to meet the Sustainable Development Goal (SDG) target of reducing MMR to below 70 by 2030.
    • Uneven Distribution: Progress remains highly uneven; while India has seen an 80% drop, many conflict-affected or economically fragile regions have seen mortality rates plateau or even rise.
    • Correction Note: Earlier reports of India’s 2023 deaths being “per lakh” were corrected in this final analysis to represent the total count of deaths for the year.

    Sources

    • The Lancet Obstetrics, Gynaecology, and Women’s Health: “Global Burden of Disease (GBD) 2023 Maternal Mortality Study” (March 2026).
    • Press Trust of India (PTI): “India’s maternal mortality ratio drops nearly 80 per cent during 1990-2023: Global analysis” (March 28, 2026).
    • Institute for Health Metrics and Evaluation (IHME): “Maternal Mortality Trends and Country Estimates” (Updated 2026).
    • Official Statement: Ministry of Health and Family Welfare, Government of India (March 28, 2026).

  • India’s Maternal Mortality Ratio Drops 86% Since 1990, Outpacing Global Average

    NEW DELHI (Saturday, March 28, 2026) — The Union Health Ministry announced today that India has achieved a historic 86% reduction in its Maternal Mortality Ratio (MMR) since 1990. This rate of decline is nearly double the global average of 48%, marking India as a top performer in maternal health among developing nations.

    Data Discrepancy: Ministry vs. The Lancet

    The Ministry’s statement comes as a reaction to a recent global analysis published in The Lancet Obstetrics, Gynaecology, and Women’s Health, which estimated India’s 2023 MMR at 116. Government officials, however, pointed to domestic data which suggests a more significant improvement.

    Data Source1990 MMR2023 MMR% Reduction
    Sample Registration System (SRS)556*88~86%
    The Lancet (IHME Study)508116~80%
    Global Average——48%

    *Historical SRS estimates for 1990 adjusted for comparison.

    Key Drivers of India’s Success

    Ministry sources attributed this “unprecedented” decline to several targeted healthcare interventions implemented over the last two decades.

    • Institutional Deliveries: The Janani Suraksha Yojana (JSY) and Janani Shishu Suraksha Karyakram (JSSK) have shifted childbirth from homes to facilities, ensuring professional medical oversight.
    • Emergency Care: The expansion of Pradhan Mantri Surakshit Matritva Abhiyan (PMSMA) provides free, quality antenatal care on the 9th of every month to pregnant women.
    • Infrastructure: Significant investment in First Referral Units (FRUs) and the “102/108” ambulance services has reduced the “Three Delays” (delay in seeking, reaching, and receiving care).
    • Midwifery Initiative: The recent focus on creating a dedicated cadre of Nurse Practitioners in Midwifery (NPMs) is expected to further humanize and improve birth outcomes.

    Road to Sustainable Development Goals (SDG)

    The United Nations Sustainable Development Goal (SDG) target is to reduce the global MMR to less than 70 per lakh live births by 2030.

    • Current Standing: With an MMR of 88 (as per SRS 2021-23), India is well-positioned to meet the SDG target ahead of the 2030 deadline.
    • Regional Performance: Several Indian states, including Kerala (19), Maharashtra (33), and Telangana (43), have already surpassed the SDG target of 70.

    Sources

    • Press Information Bureau (PIB): “India achieves landmark 86% reduction in Maternal Mortality since 1990” (March 28, 2026).
    • Sample Registration System (SRS): Special Bulletin on Maternal Mortality in India 2021-23 (Published March 2026).
    • The Lancet: “Global, regional, and national estimates of maternal mortality, 1990–2023” (Published March 2026).
    • Ministry of Health & Family Welfare (MoHFW): Annual Progress Report on Maternal Health (2025-26).

  • Study: Vitamin B12 Intake During Pregnancy Aids Infant Brain Development

    NEW DELHI (Saturday, March 28, 2026) — A landmark study published in BMJ Paediatrics Open has established a direct link between Vitamin B12 supplementation in pregnant vegetarian women and improved early brain development in their infants. The research, conducted across centers in India and Nepal, highlights a critical nutritional intervention for regions with high vegetarian populations where B12 deficiency is often endemic.

    Key Findings: The Impact of Supplementation

    The study focused on pregnant women with traditionally low B12 intake and tracked the neurodevelopmental outcomes of their children.

    • Brain Development: Babies born to mothers with higher Vitamin B12 levels showed significantly better scores in early cognitive and motor development tests.
    • Maternal Health: Supplementation substantially reduced the prevalence of maternal Vitamin B12 deficiency, which is linked to anemia and fatigue.
    • Target Group: The benefits were most pronounced in vegetarian mothers, who naturally lack B12 sources typically found in meat, fish, and eggs.

    Expert Insight: Dr. Jitender Nagpal

    Dr. Jitender Nagpal, Deputy Medical Director at the Sitaram Bhartia Institute of Science and Research (Delhi), who led the Indian arm of the study, emphasized the clinical importance of these findings:

    “The findings provide strong evidence that improving Vitamin B12 intake during pregnancy in vegetarian mothers can benefit early brain development in babies while substantially reducing maternal Vitamin B12 deficiency.”

    Understanding the B12 Connection

    Vitamin B12 (Cobalamin) is essential for the formation of the myelin sheath, the protective coating of nerves that allows for rapid signal transmission in the brain.

    FeatureImportance in Pregnancy
    Neural TubeEssential for the early formation of the baby’s central nervous system.
    Cognitive FunctionDirectly impacts memory and learning capabilities in the first year of life.
    Metabolic HealthHelps regulate homocysteine levels; high levels are linked to pregnancy complications.

    [Image: Infographic showing dietary sources of Vitamin B12 for vegetarians (Milk, Curd, Paneer, Fortified Cereals) vs. Non-vegetarians]

    The Global Collaboration

    The research was a joint effort between:

    • India: Sitaram Bhartia Institute of Science and Research, New Delhi.
    • Nepal: Various healthcare centers in collaboration with local researchers.
    • United Kingdom: Academic partners providing statistical and analytical support.

    Sources

    • BMJ Paediatrics Open: “Impact of Vitamin B12 supplementation on infant neurodevelopment” (Published March 2026).
    • The Times of India: “Higher Vitamin B12 intake by pregnant women can aid early brain development in babies” (March 28, 2026).
    • Press Trust of India (PTI): “Study finds B12 vital for brain development in babies of veg mothers” (March 28, 2026).
    • Hindustan Times: “New research highlights need for B12 during pregnancy in India” (March 28, 2026).

    Next Step: Since your startup Ayen.in aims to sim

  • A new global analysis published in The Lancet Obstetrics, Gynaecology, & Women’s Health on March 26, 2026, has identified India as one of the countries with the highest absolute number of maternal deaths in 2023. The study, conducted by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, provides a comprehensive look at maternal mortality trends across 204 countries.

    Key Data for 2023

    The report clarifies that while India has made significant strides in maternal health, the absolute volume of deaths remains high due to the country’s large population and birth rate.

    CountryTotal Maternal Deaths (2023)Maternal Mortality Ratio (MMR)
    Nigeria32,900Highest global total
    India24,700116 per 1 lakh live births
    Ethiopia11,900Concentrated in sub-Saharan Africa
    Pakistan10,300High burden in South Asia

    Global and Regional Trends

    The analysis, part of the Global Burden of Disease (GBD) 2023 research, highlights that progress in reducing maternal deaths has slowed globally since 2015.

    • Global Burden: The world saw a total of 2.4 lakh maternal deaths in 2023. The global maternal mortality ratio stands at 190.5 per lakh live births, a decline of more than one-third since 1990.
    • Leading Causes: Maternal haemorrhage (excessive bleeding) and hypertensive disorders (such as pre-eclampsia) continue to be the primary causes, responsible for over 40% of deaths globally.
    • SDG Targets: 104 out of 204 countries have yet to meet the Sustainable Development Goal (SDG) target of reducing the MMR to below 70 per lakh live births by 2030.

    India’s Progress and Discrepancies

    While the IHME study estimates India’s MMR at 116, domestic data from the Union Health Ministry paints a more optimistic picture of the country’s trajectory.

    • Official Indian Figures: According to the latest Sample Registration System (SRS) 2021-23, India’s MMR stands at 88 per lakh live births.
    • Unprecedented Decline: Government sources highlight an 86% reduction in MMR since 1990, significantly higher than the global average reduction of 48%. This success is attributed to programs like Janani Suraksha Yojana (JSY) and improved access to institutional deliveries.
    • Impact of COVID-19: The IHME study noted that the pandemic caused temporary setbacks in maternal mortality during 2020–2021 before widespread vaccination, though most regions have since returned to pre-pandemic trends.

    Sources

    • The Lancet Obstetrics, Gynaecology, & Women’s Health: “Global Burden of Disease (GBD) 2023 Maternal Mortality Study” (Published March 2026).
    • Institute for Health Metrics and Evaluation (IHME): “Global maternal deaths fell to 240,000 in 2023” (Official Release, March 26, 2026).
    • Press Trust of India (PTI): “India among countries with highest total maternal deaths in 2023: Global analysis” (Updated March 28, 2026).
    • UN-MMEIG Report: “Trends in Maternal Mortality 2000 to 2023” (Published April 2025).

  • Study Reveals Metformin Controls Blood Sugar via Brain Pathways

    NEW DELHI (Thursday, March 26, 2026) — A groundbreaking study published in the journal Science Advances has revealed that metformin, the world’s most widely prescribed diabetes medication, works by targeting a previously unknown pathway in the brain. For over 60 years, it was believed the drug acted solely on the liver and gut; however, this discovery identifies the brain as a “command center” for its glucose-lowering effects.

    The Discovery: The Rap1-Hypothalamus Axis

    Researchers at Baylor College of Medicine, led by Dr. Makoto Fukuda, identified a specific molecular “switch” in the brain that allows metformin to function at much lower doses than previously thought necessary.

    • The Target Region: The study focused on the ventromedial hypothalamus (VMH), a part of the brain responsible for sensing glucose and regulating satiety.
    • The Molecular Switch: A protein called Rap1 was found to be the key mediator. Metformin works by suppressing Rap1 activity in the VMH.
    • Neural Activation: When Rap1 is inhibited, it activates a specific group of brain cells called SF1 neurons, which then send signals to the rest of the body to lower blood sugar.

    Key Evidence from the Study

    The research team used genetically engineered models to prove that the brain is indispensable for metformin’s action.

    Experiment TypeMethodologyResult
    Genetic KnockoutMice were bred without the Rap1 protein in their brain’s VMH.Metformin failed to lower blood sugar, even though other drugs like insulin still worked.
    Direct Brain InjectionTiny doses of metformin were injected directly into the brains of diabetic mice.Blood sugar dropped significantly at doses thousands of times lower than typical oral doses.
    Sensitivity ComparisonCompared the brain’s response to the liver and gut’s response.The brain reacted to much lower concentrations, suggesting it is a primary site of action.

    Implications for the Future

    This shift in understanding opens new therapeutic doors for treating type 2 diabetes and potentially other neurological conditions.

    1. Targeted Therapies: Future drugs could be designed to target the VMH Rap1 pathway directly, potentially reducing the side effects (like gastrointestinal distress) associated with high oral doses of metformin.
    2. Anti-Aging Potential: Metformin is already widely studied for its geroprotective (anti-aging) benefits. Dr. Fukuda’s team plans to investigate if this same Rap1 signaling is responsible for the drug’s ability to slow brain aging and improve longevity.
    3. Refined Prescribing: Doctors can now better understand why low doses of metformin are effective for some patients, as the brain-based mechanism is highly sensitive.

    Sources

    • Science Advances: Lin et al., “Low-dose metformin requires brain Rap1 for its antidiabetic action” (Published March 2026).
    • Baylor College of Medicine News: “Researchers uncover a new player mediating metformin’s anti-diabetic action” (March 26, 2026).
    • The Week: “Diabetes drug’s 60-year mystery solved: Scientists finally discovered how metformin works” (March 26, 2026).

  • A new global analysis published in The Lancet Obstetrics, Gynaecology, and Women’s Health has highlighted a significant, though slowing, decline in maternal mortality worldwide. While the report acknowledges long-term progress, it places India among the countries with the highest absolute number of maternal deaths in 2023.

    Global Maternal Mortality Estimates (2023)

    The study, led by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, reveals a stark disparity in maternal health outcomes across South Asia and Sub-Saharan Africa.

    CountryMaternal Deaths (Total)Comparison to Live Births
    Nigeria32,900Highest global total.
    India24,700Second highest global total.
    Ethiopia11,900High burden in Sub-Saharan Africa.
    Pakistan10,300High burden in South Asia.

    Correction on Ratio: It is important to distinguish between absolute deaths and the Maternal Mortality Ratio (MMR). While India saw 24,700 deaths in total, its MMR (deaths per 100,000 live births) has actually seen a steady decline. According to the Sample Registration System (SRS) and the latest UN-MMEIG reports (2025), India’s MMR has dropped to approximately 93 per lakh live births, down from 130 in 2014-16.

    Key Findings of the IHME Analysis

    The researchers noted that while maternal deaths have decreased significantly over the past three decades, the pace of improvement has stagnated in recent years.

    • Uneven Progress: Improvements are not uniform; while some regions have seen rapid declines due to better access to emergency obstetric care, others remain trapped by fragile health systems.
    • South Asia Context: India and Pakistan continue to account for a large portion of global maternal deaths primarily due to their large population sizes and high birth rates, despite improving ratios.
    • Stagnation Drivers: Factors such as climate change, regional conflicts, and the long-term impact of the COVID-19 pandemic on routine prenatal services have contributed to the slowing progress.

    India’s Progress vs. The Global Burden

    Despite the high absolute number of deaths, the Ministry of Health and Family Welfare points to India as a “top performer” in reducing the rate of mortality:

    • 86% Decline: India has reduced its MMR by 86% over the last 33 years (1990–2023), outpacing the global average reduction of 48%.
    • SDG Targets: India is currently on track to achieve the Sustainable Development Goal (SDG) target of an MMR below 70 per lakh live births by 2030.

    Sources

    • The Lancet Obstetrics, Gynaecology, and Women’s Health: “Global, regional, and national estimates of maternal mortality, 1990–2023” (Published March 2026).
    • Press Information Bureau (PIB): “India witnesses a steady downward trend in maternal and child mortality” (April 7, 2025).
    • Institute for Health Metrics and Evaluation (IHME): “Maternal Mortality Trends and Country Estimates” (Updated 2026).
    • UN Maternal Mortality Estimation Inter-agency Group (UN-MMEIG): “2000-2023 Report” (Published April 2025).

  • De-prescribing Preventive Drugs in Frail Elderly Not Linked to Higher Mortality

    NEW DELHI (Friday, March 27, 2026) — A collaborative global analysis has found that stopping “preventive” medications in frail, older adults does not increase the risk of death, hospitalization, or major cardiovascular events. The findings, published in the journal BMC Geriatrics, challenge the long-held medical practice of maintaining lifelong preventive drug regimens for patients with limited life expectancy or high frailty.

    The Study: Re-evaluating Polypharmacy

    The research was conducted by an international team, including experts from the ICMR-National Institute for Research in Bacterial Infections (Kolkata) and Sweden’s Karolinska Institutet. They analyzed multiple studies to determine if “de-prescribing”—the planned process of reducing or stopping medications—led to adverse health outcomes.

    • Target Group: Older adults (typically 65+) classified as “frail” or having multiple chronic conditions.
    • Medications Studied: Primary preventive drugs such as statins (for cholesterol), antihypertensives (for blood pressure), and bisphosphonates (for bone density).
    • Key Findings: * No significant increase in mortality or hospitalization rates.
      • No rise in Major Adverse Cardiovascular Events (MACE).
      • No increased risk of falls or fractures, which are leading causes of disability in seniors.
      • No recorded reduction in the quality of life.

    [Image: Infographic showing the “De-prescribing Process”: Review > Identify > Prioritize > Plan > Monitor]

    Why “De-prescribing” Matters

    As patients age, the benefit-to-risk ratio of certain preventive drugs shifts. What was beneficial at age 50 may become a burden at age 85.

    FactorRisk of Over-Medication (Polypharmacy)
    Adverse Drug ReactionsOlder metabolism processes drugs slower, leading to higher toxicity risk.
    Drug InteractionsTaking 5+ medications significantly increases the chance of harmful interactions.
    Physical HazardsCertain BP meds can cause dizziness, leading to falls and hip fractures.
    Treatment BurdenThe mental and financial stress of managing dozens of daily pills.

    A Note on “Low Evidence Certainty”

    Despite the encouraging results, the researchers issued a caveat. The “evidence certainty”—the statistical confidence that the research perfectly reflects reality—was rated as low.

    • The Need for Trials: Most existing data comes from observational studies rather than large-scale Randomized Controlled Trials (RCTs).
    • Clinical Judgment: Experts emphasize that de-prescribing should never be done by the patient alone; it must be a supervised clinical decision tailored to the individual’s specific health status and goals.

    Sources

    • BMC Geriatrics: “Effect of de-prescribing preventive medications on mortality and health outcomes in frail older adults: A systematic review” (Published March 2026).
    • Press Trust of India (PTI): “Stopping preventive drugs in elderly not linked to mortality, hospitalisation: Analysis” (March 27, 2026).
    • Karolinska Institutet Press: “New research questions lifelong preventive medication for the frail elderly” (March 26, 2026).
    • ICMR Bulletin: “Geriatric Health Update: De-prescribing Protocols” (March 2026).

  • AIIMS Delhi Surgeons Successfully Remove 21.8 kg Uterine Sarcoma in Rare Feat

    NEW DELHI (Friday, March 27, 2026) — Surgeons at AIIMS Delhi’s Dr. B.R. Ambedkar Institute Rotary Cancer Hospital (Dr. BRA-IRCH) have successfully performed a high-risk operation to remove a massive 21.8 kg uterine sarcoma tumor from a 46-year-old woman. The tumor, which filled the patient’s entire abdominal and pelvic cavities, is one of the largest of its kind ever recorded in Indian medical history.

    The Patient: A High-Risk Case

    The 46-year-old Delhi resident presented with a rapidly deteriorating condition that had progressed over four months.

    • Symptoms: Progressive abdominal fullness, severe distension, and intense pain that eventually led to significant functional limitations.
    • Comorbidities: The patient was recently diagnosed with diabetes and hypertension, complicating the anesthesia and surgical recovery process.
    • Clinical Surprise: Despite the immense pressure on her internal organs, she reported no bowel or bladder issues, which is unusual for a mass of this magnitude.

    The Surgery: Precision Under Pressure

    The operation was led by Dr. M.D. Ray, Professor in the Department of Surgical Oncology. The surgical team faced immense challenges due to the tumor’s size and its proximity to vital organs.

    Surgical ChallengeMedical Response
    Tumor Weight21.8 kg (Filling abdomen and pelvis).
    Organ CompressionThe mass pushed the diaphragm and major blood vessels (Aorta/IVC).
    Vascular RiskPotential for massive blood loss during the detachment of the uterine wall.
    Operation TimeSeveral hours of meticulously separating the mass from the intestines and bladder.

    Understanding Uterine Sarcoma

    Uterine sarcoma is a rare, aggressive form of cancer that forms in the muscles or supporting tissues of the uterus.

    • Difference from Fibroids: Unlike common non-cancerous fibroids, sarcomas grow rapidly and can spread to other parts of the body.
    • Detection: Large sarcomas are often mistaken for simple bloating or weight gain until they reach a size that causes severe physical distress.
    • Treatment: Surgical removal (Hysterectomy) remains the primary treatment, often followed by radiation or chemotherapy depending on the “grade” of the tumor.

    Post-Operative Recovery

    The patient is currently stable and under close observation at Dr. BRA-IRCH. Dr. Ray noted that the successful removal of such a “gigantic mass” without damaging the surrounding organs is a testament to the advanced surgical oncology capabilities at AIIMS.

    Sources

    • The Hindu: “AIIMS Delhi surgeons remove 21.8 kg uterine sarcoma tumour in high-risk operation” (March 27, 2026).
    • Press Trust of India (PTI): “Rare 21.8 kg tumor removed from 46-year-old woman at AIIMS Delhi” (March 27, 2026).
    • Times of India: “AIIMS Delhi: Massive 21 kg uterine sarcoma removed in record surgery” (March 27, 2026).
    • Official AIIMS Bulletin: “Department of Surgical Oncology Achievement Report” (March 2026).